Amgen to Develop Preclinical Cancer Immunotherapy for Advaxis

Source: Genetic, Engineering & Biotechnology News

Aug 03, 2016

Amgen will develop and commercialize Advaxis’ ADXS-NEO, a preclinical cancer immunotherapy candidate, through a global agreement that could generate more than $540 million for Advaxis, as reported by Genetic, Engineering & Biotechnology News.

According to the report, ADXS-NEO is designed to activate a patient's immune system to respond against the neoepitopes contained in and identified from each individual patient's tumor. The collaboration is designed to combine Amgen's development expertise in immuno-oncology with Advaxis' MINE (My Immunotherapy Neo-Epitopes) program.

The companies plan to develop patient-specific immunotherapy constructs that incorporate the neoepitope sequences identified in the patient's tumor cells. Clinical studies using ADXS-NEO are in development and expected to begin in 2017.

Read the full article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments